Medullary Thyroid Carcinoma

1. Front Matter

   Pages i-viii

   PDF

2. Thyroid C-Cell Biology and Oncogenic Transformation

   • Gilbert J. Cote, Elizabeth G. Grubbs, Marie-Claude Hofmann

   Pages 1-39

3. Histopathology of C Cells and Medullary Thyroid Carcinoma

   • Kurt Werner Schmid

   Pages 41-60

4. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma

   • Friedhelm Raue, Karin Frank-Raue

   Pages 61-90

5. Medullary Thyroid Carcinoma: Imaging

   • Stefan Delorme, Friedhelm Raue

   Pages 91-116

6. Calcitonin as Biomarker for the Medullary Thyroid Carcinoma

   • Yoon Ju Bae, Michael Schaab, Juergen Kratzsch

   Pages 117-137

7. Hereditary Medullary Thyroid Cancer Genotype–Phenotype Correlation

   • Karin Frank-Raue, Friedhelm Raue

   Pages 139-156

8. Pheochromocytomas in Multiple Endocrine Neoplasia Type 2

   • Venessa H. M. Tsang, Lyndal J. Tacon, Diana L. Learoyd, Bruce G. Robinson

   Pages 157-178

9. Primary Hyperparathyroidism in MEN2 Syndromes

   • Maria Alevizaki, Katerina Saltiki

   Pages 179-186

10. Surgical Treatment of Medullary Thyroid Cancer

    • Andreas Machens, Henning Dralle

    Pages 187-205

11. Long-Term Follow-up in Medullary Thyroid Carcinoma

    • Friedhelm Raue, Karin Frank-Raue

    Pages 207-225

12. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma

    • Ramona Dadu, Mimi N. Hu, Elizabeth G. Grubbs, Robert F. Gagel

    Pages 227-249

This book offers a comprehensive overview of medullary thyroid carcinoma, both in the more common sporadic form and in the familial form, multiple endocrine neoplasia (MEN) types 2A and 2B. The coverage includes, but is not limited to, molecular biology and genetics, pathology, clinical presentation, imaging techniques, surgical treatment, and follow-up. The role of calcitonin as a highly sensitive and specific tumor marker for the screening, diagnosis, and follow-up of MTC and metastatic disease is described, and the significance of other tumor markers is also considered. With regard to treatment, the use of thyroidectomy is fully discussed, including in children carrying the mutations in the RET proto-oncogene considered causative for MEN 2. Additionally, the value of tyrosine kinase inhibitors as the most effective treatment modality in patients with a large tumor burden or rapid tumor growth, or both, is explained. Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2 will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.

• Calcitonin
• Medullary Thyroid Carcinoma
• Multiple Endocrine Neoplasia Type 2
• Pheochromocytoma
• RET protooncogene

• Endocrine Practice and Molecular Laboratory, Medical Faculty, University of Heidelberg , Heidelberg, Germany

  Friedhelm Raue

Policies and ethics